Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1.

JAAD case reports

Merati M, Buethe DJ, Cooper KD, Honda KS, Wang H, Gerstenblith MR.
PMID: 27051737
JAAD Case Rep. 2015 Jun 25;1(4):227-9. doi: 10.1016/j.jdcr.2015.05.003. eCollection 2015 Jul.

No abstract available.

Cite
Merati M, Buethe DJ, Cooper KD, et al. Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1. JAAD Case Rep. 2015;1(4):227-9doi: 10.1016/j.jdcr.2015.05.003.
Merati, M., Buethe, D. J., Cooper, K. D., Honda, K. S., Wang, H., & Gerstenblith, M. R. (2015). Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1. JAAD case reports, 1(4), 227-9. https://doi.org/10.1016/j.jdcr.2015.05.003
Merati, Miesha, et al. "Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1." JAAD case reports vol. 1,4 (2015): 227-9. doi: https://doi.org/10.1016/j.jdcr.2015.05.003
Merati M, Buethe DJ, Cooper KD, Honda KS, Wang H, Gerstenblith MR. Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1. JAAD Case Rep. 2015 Jun 25;1(4):227-9. doi: 10.1016/j.jdcr.2015.05.003. eCollection 2015 Jul. PMID: 27051737; PMCID: PMC4808729.
Copy Download .nbib Format: NLM
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.

JACC. Basic to translational science

Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ.
PMID: 34904132
JACC Basic Transl Sci. 2021 Dec 08; doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08.

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients...

Cite
Leucker TM, Osburn WO, Reventun P, et al. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021;doi: 10.1016/j.jacbts.2021.09.013.
Leucker, T. M., Osburn, W. O., Reventun, P., Smith, K., Claggett, B., Kirwan, B. A., de Brouwer, S., Williams, M. S., Gerstenblith, G., Hager, D. N., Streiff, M. B., Solomon, S. D., & Lowenstein, C. J. (2021). Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC. Basic to translational science, . https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker, Thorsten M, et al. "Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial." JACC. Basic to translational science vol. (2021). doi: https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021 Dec 08; doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08. PMID: 34904132; PMCID: PMC8653991.
Copy Download .nbib Format: NLM
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.

JACC. Basic to translational science

Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ.
PMID: 34904132
JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08.

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients...

Cite
Leucker TM, Osburn WO, Reventun P, et al. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021;6(12):935-945doi: 10.1016/j.jacbts.2021.09.013.
Leucker, T. M., Osburn, W. O., Reventun, P., Smith, K., Claggett, B., Kirwan, B. A., de Brouwer, S., Williams, M. S., Gerstenblith, G., Hager, D. N., Streiff, M. B., Solomon, S. D., & Lowenstein, C. J. (2021). Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC. Basic to translational science, 6(12), 935-945. https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker, Thorsten M, et al. "Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial." JACC. Basic to translational science vol. 6,12 (2021): 935-945. doi: https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08. PMID: 34904132; PMCID: PMC8653991.
Copy Download .nbib Format: NLM
Metastastic vulvar squamous cell carcinoma mimicking genital herpes.

JAAD case reports

Bahner JD, Scott JF, Shoureshi P, Honda K, Gerstenblith MR.
PMID: 27752532
JAAD Case Rep. 2016 Oct 06;2(5):387-389. doi: 10.1016/j.jdcr.2016.08.004. eCollection 2016 Sep.

No abstract available.

Cite
Bahner JD, Scott JF, Shoureshi P, et al. Metastastic vulvar squamous cell carcinoma mimicking genital herpes. JAAD Case Rep. 2016;2(5):387-389doi: 10.1016/j.jdcr.2016.08.004.
Bahner, J. D., Scott, J. F., Shoureshi, P., Honda, K., & Gerstenblith, M. R. (2016). Metastastic vulvar squamous cell carcinoma mimicking genital herpes. JAAD case reports, 2(5), 387-389. https://doi.org/10.1016/j.jdcr.2016.08.004
Bahner, Jennifer D, et al. "Metastastic vulvar squamous cell carcinoma mimicking genital herpes." JAAD case reports vol. 2,5 (2016): 387-389. doi: https://doi.org/10.1016/j.jdcr.2016.08.004
Bahner JD, Scott JF, Shoureshi P, Honda K, Gerstenblith MR. Metastastic vulvar squamous cell carcinoma mimicking genital herpes. JAAD Case Rep. 2016 Oct 06;2(5):387-389. doi: 10.1016/j.jdcr.2016.08.004. eCollection 2016 Sep. PMID: 27752532; PMCID: PMC5061298.
Copy Download .nbib Format: NLM
The triadic effect: Associations among the supervisory working alliance, therapeutic working alliance, and therapy session evaluation.

Journal of counseling psychology

Gerstenblith JA, Kline KV, Hill CE, Kivlighan DM.
PMID: 34570538
J Couns Psychol. 2021 Sep 27; doi: 10.1037/cou0000567. Epub 2021 Sep 27.

Several theorists (Bandura, 1969; Hackney & Goodyear, 1984; Searles, 1955) suggest parallels between the relationship in supervision and the relationship in therapy. We examined supervisor and therapist trainee ratings of supervisory working alliance (SWA) in 1 week predicting client-rated...

Cite
Gerstenblith JA, Kline KV, Hill CE, et al. The triadic effect: Associations among the supervisory working alliance, therapeutic working alliance, and therapy session evaluation. J Couns Psychol. 2021;doi: 10.1037/cou0000567.
Gerstenblith, J. A., Kline, K. V., Hill, C. E., & Kivlighan, D. M. (2021). The triadic effect: Associations among the supervisory working alliance, therapeutic working alliance, and therapy session evaluation. Journal of counseling psychology, . https://doi.org/10.1037/cou0000567
Gerstenblith, Judith A, et al. "The triadic effect: Associations among the supervisory working alliance, therapeutic working alliance, and therapy session evaluation." Journal of counseling psychology vol. (2021). doi: https://doi.org/10.1037/cou0000567
Gerstenblith JA, Kline KV, Hill CE, Kivlighan DM. The triadic effect: Associations among the supervisory working alliance, therapeutic working alliance, and therapy session evaluation. J Couns Psychol. 2021 Sep 27; doi: 10.1037/cou0000567. Epub 2021 Sep 27. PMID: 34570538.
Copy Download .nbib Format: NLM
HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study.

Scientific reports

Kolossváry M, Celentano D, Gerstenblith G, Bluemke DA, Mandler RN, Fishman EK, Bhatia S, Chen S, Lai S, Lai H.
PMID: 34848791
Sci Rep. 2021 Nov 30;11(1):23110. doi: 10.1038/s41598-021-02556-w.

Our objective was to assess whether human immunodeficiency virus (HIV)-infection directly or indirectly promotes the progression of clinical characteristics of coronary artery disease (CAD). 300 African Americans with asymptomatic CAD (210 male; age: 48.0 ± 7.2 years; 226 HIV-infected)...

Cite
Kolossváry M, Celentano D, Gerstenblith G, et al. HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study. Sci Rep. 2021;11(1):23110doi: 10.1038/s41598-021-02556-w.
Kolossváry, M., Celentano, D., Gerstenblith, G., Bluemke, D. A., Mandler, R. N., Fishman, E. K., Bhatia, S., Chen, S., Lai, S., & Lai, H. (2021). HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study. Scientific reports, 11(1), 23110. https://doi.org/10.1038/s41598-021-02556-w
Kolossváry, Márton, et al. "HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study." Scientific reports vol. 11,1 (2021): 23110. doi: https://doi.org/10.1038/s41598-021-02556-w
Kolossváry M, Celentano D, Gerstenblith G, Bluemke DA, Mandler RN, Fishman EK, Bhatia S, Chen S, Lai S, Lai H. HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study. Sci Rep. 2021 Nov 30;11(1):23110. doi: 10.1038/s41598-021-02556-w. PMID: 34848791; PMCID: PMC8632934.
Copy Download .nbib Format: NLM
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.

JACC. Basic to translational science

Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ.
PMID: 34904132
JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08.

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients...

Cite
Leucker TM, Osburn WO, Reventun P, et al. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021;6(12):935-945doi: 10.1016/j.jacbts.2021.09.013.
Leucker, T. M., Osburn, W. O., Reventun, P., Smith, K., Claggett, B., Kirwan, B. A., de Brouwer, S., Williams, M. S., Gerstenblith, G., Hager, D. N., Streiff, M. B., Solomon, S. D., & Lowenstein, C. J. (2021). Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC. Basic to translational science, 6(12), 935-945. https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker, Thorsten M, et al. "Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial." JACC. Basic to translational science vol. 6,12 (2021): 935-945. doi: https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08. PMID: 34904132; PMCID: PMC8653991.
Copy Download .nbib Format: NLM
HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study.

Scientific reports

Kolossváry M, Celentano D, Gerstenblith G, Bluemke DA, Mandler RN, Fishman EK, Bhatia S, Chen S, Lai S, Lai H.
PMID: 34848791
Sci Rep. 2021 Nov 30;11(1):23110. doi: 10.1038/s41598-021-02556-w.

Our objective was to assess whether human immunodeficiency virus (HIV)-infection directly or indirectly promotes the progression of clinical characteristics of coronary artery disease (CAD). 300 African Americans with asymptomatic CAD (210 male; age: 48.0 ± 7.2 years; 226 HIV-infected)...

Cite
Kolossváry M, Celentano D, Gerstenblith G, et al. HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study. Sci Rep. 2021;11(1):23110doi: 10.1038/s41598-021-02556-w.
Kolossváry, M., Celentano, D., Gerstenblith, G., Bluemke, D. A., Mandler, R. N., Fishman, E. K., Bhatia, S., Chen, S., Lai, S., & Lai, H. (2021). HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study. Scientific reports, 11(1), 23110. https://doi.org/10.1038/s41598-021-02556-w
Kolossváry, Márton, et al. "HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study." Scientific reports vol. 11,1 (2021): 23110. doi: https://doi.org/10.1038/s41598-021-02556-w
Kolossváry M, Celentano D, Gerstenblith G, Bluemke DA, Mandler RN, Fishman EK, Bhatia S, Chen S, Lai S, Lai H. HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study. Sci Rep. 2021 Nov 30;11(1):23110. doi: 10.1038/s41598-021-02556-w. PMID: 34848791; PMCID: PMC8632934.
Copy Download .nbib Format: NLM
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.

JACC. Basic to translational science

Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ.
PMID: 34904132
JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08.

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients...

Cite
Leucker TM, Osburn WO, Reventun P, et al. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021;6(12):935-945doi: 10.1016/j.jacbts.2021.09.013.
Leucker, T. M., Osburn, W. O., Reventun, P., Smith, K., Claggett, B., Kirwan, B. A., de Brouwer, S., Williams, M. S., Gerstenblith, G., Hager, D. N., Streiff, M. B., Solomon, S. D., & Lowenstein, C. J. (2021). Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC. Basic to translational science, 6(12), 935-945. https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker, Thorsten M, et al. "Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial." JACC. Basic to translational science vol. 6,12 (2021): 935-945. doi: https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08. PMID: 34904132; PMCID: PMC8653991.
Copy Download .nbib Format: NLM
Therapist challenges and client responses in psychodynamic psychotherapy: An empirically supported case study.

Psychotherapy (Chicago, Ill.)

Hill CE, Morales K, Gerstenblith JA, Bansal P, An M, Rim K, Kivlighan DM.
PMID: 35025565
Psychotherapy (Chic). 2022 Jan 13; doi: 10.1037/pst0000424. Epub 2022 Jan 13.

In this case study of an adult female client working with a doctoral student female therapist in 85 sessions of individual psychodynamic psychotherapy, we analyzed the antecedents, challenges, and consequences for 53 challenges in the intake and first five...

Cite
Hill CE, Morales K, Gerstenblith JA, et al. Therapist challenges and client responses in psychodynamic psychotherapy: An empirically supported case study. Psychotherapy (Chic). 2022;doi: 10.1037/pst0000424.
Hill, C. E., Morales, K., Gerstenblith, J. A., Bansal, P., An, M., Rim, K., & Kivlighan, D. M. (2022). Therapist challenges and client responses in psychodynamic psychotherapy: An empirically supported case study. Psychotherapy (Chicago, Ill.), . https://doi.org/10.1037/pst0000424
Hill, Clara E, et al. "Therapist challenges and client responses in psychodynamic psychotherapy: An empirically supported case study." Psychotherapy (Chicago, Ill.) vol. (2022). doi: https://doi.org/10.1037/pst0000424
Hill CE, Morales K, Gerstenblith JA, Bansal P, An M, Rim K, Kivlighan DM. Therapist challenges and client responses in psychodynamic psychotherapy: An empirically supported case study. Psychotherapy (Chic). 2022 Jan 13; doi: 10.1037/pst0000424. Epub 2022 Jan 13. PMID: 35025565.
Copy Download .nbib Format: NLM
Scurvy in a patient on vemurafenib.

JAAD case reports

Gerstenblith MR, Petukhova TA, Koon HB.
PMID: 27075135
JAAD Case Rep. 2014 Nov 01;1(1):32-3. doi: 10.1016/j.jdcr.2014.10.008. eCollection 2015 Jan.

No abstract available.

Cite
Gerstenblith MR, Petukhova TA, Koon HB. Scurvy in a patient on vemurafenib. JAAD Case Rep. 2014;1(1):32-3doi: 10.1016/j.jdcr.2014.10.008.
Gerstenblith, M. R., Petukhova, T. A., & Koon, H. B. (2015). Scurvy in a patient on vemurafenib. JAAD case reports, 1(1), 32-3. https://doi.org/10.1016/j.jdcr.2014.10.008
Gerstenblith, Meg R, et al. "Scurvy in a patient on vemurafenib." JAAD case reports vol. 1,1 (2015): 32-3. doi: https://doi.org/10.1016/j.jdcr.2014.10.008
Gerstenblith MR, Petukhova TA, Koon HB. Scurvy in a patient on vemurafenib. JAAD Case Rep. 2014 Nov 01;1(1):32-3. doi: 10.1016/j.jdcr.2014.10.008. eCollection 2015 Jan. PMID: 27075135; PMCID: PMC4802555.
Copy Download .nbib Format: NLM
Stable ischemic heart disease: how to keep it that way.

The Journal of clinical investigation

Leucker TM, Schulman SP, Gerstenblith G.
PMID: 31985489
J Clin Invest. 2020 Mar 02;130(3):1055-1057. doi: 10.1172/JCI135959.

No abstract available.

Cite
Leucker TM, Schulman SP, Gerstenblith G. Stable ischemic heart disease: how to keep it that way. J Clin Invest. 2020;130(3):1055-1057doi: 10.1172/JCI135959.
Leucker, T. M., Schulman, S. P., & Gerstenblith, G. (2020). Stable ischemic heart disease: how to keep it that way. The Journal of clinical investigation, 130(3), 1055-1057. https://doi.org/10.1172/JCI135959
Leucker, Thorsten M, et al. "Stable ischemic heart disease: how to keep it that way." The Journal of clinical investigation vol. 130,3 (2020): 1055-1057. doi: https://doi.org/10.1172/JCI135959
Leucker TM, Schulman SP, Gerstenblith G. Stable ischemic heart disease: how to keep it that way. J Clin Invest. 2020 Mar 02;130(3):1055-1057. doi: 10.1172/JCI135959. PMID: 31985489; PMCID: PMC7269554.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries